Nuvation Bio Expands Phase 3 Safusidenib Glioma Trial to Six European Countries

• Nuvation Bio will expand its pivotal Phase 3 SIGMA trial of investigational safusidenib for IDH1-mutant glioma to six European countries.
• The expansion broadens a study already enrolling or preparing to enroll patients across five countries outside Europe.
• The placebo-controlled trial will evaluate maintenance treatment following standard therapy in approximately 300 patients with high-risk IDH1-mutant astrocytoma.
• Future results will assess whether safusidenib delays disease progression.
• An exploratory cohort will evaluate approximately 40 patients with grade 3 IDH1-mutant oligodendroglioma who have not received chemotherapy or radiotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY82753) on October 29, 2026, and is solely responsible for the information contained therein.